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INTRODUCTION
The neurovirulence of most noncytolytic viruses that
infect the brain is associated with the inflammatory re-
sponses they induce. Examples include coronaviruses
(Lane and Buchmeier, 1997), Borna (Morimoto et al.,
1996), lymphocytic choriomeningitis virus (Buchmeier et
al., 1980) and Theiler’s encephalomyelitis virus (Lipton
and Jelachich, 1997). Infiltration of immune cells and
disregulation of immune responses in the central ner-
vous system are principally responsible for the clinical
manifestations of these diseases. However, there are
other agents that are neuropathogenic but that do not
provoke inflammatory infiltrates. These include the trans-
missible spongiform encephalopathies (‘‘prion’’ diseases)
(DeArmond and Prusiner, 1998) and the neurodegenera-
tive diseases caused by the murine oncornaviruses (An-
drews and Gardner, 1974). The pathogenesis of these
diseases appears to revolve purely around the interac-
tion of the agent with cells intrinsic to the brain. In this
review, we will discuss the principal viral and host de-
terminants of neurovirulence induced by the oncornavi-
ruses as well as the cellular players involved in the
pathogenesis of these diseases.
Discovery and characterization of the Lake Casitas
virus
In the early 1970s, Gardner and colleagues (1973)
isolated an oncornavirus from the brains of wild mice at
Lake Casitas in southern California. The virus, which
was subsequently named Wild Mouse Virus or CasBrE,
is mouse tropic (ecotropic) (Hartley and Rowe, 1976) and
is endemic in this mouse population (Gardner et al.,
1976a,b). It is transmitted in external secretions (Gardner
et al., 1979; Portis et al., 1987), primarily from mother to
pup in the milk but also, among adults, by sexual inter-
course and fighting. The provirus was not found to be
present in the germline (Barbacid et al., 1979). Mice
inoculated as neonates develop a persistent and produc-
tive infection in many tissues of the body and exhibit a
life-long viremia. Rarely (;10%) these mice develop a
neurological disease manifested by tremor and paraly-
sis with a long incubation period (preclinical period)
ranging from several months to more than a year (Hen-
derson et al., 1974). The neuropathology is characterized
by spongiform neurodegeneration primarily involving the
motor system of the brain and spinal cord and associ-
ated with intense reactive gliosis and neuronal dropout
(Andrews and Gardner, 1974; Brooks et al., 1980). Infiltra-
tion of inflammatory cells from the periphery is notice-
ably absent. Though this disease bears a striking resem-
blance pathologically to the prion diseases (Brooks et al.,
1980; Hoffman et al., 1982), CasBrE is a conventional
virus that is readily inactivated by heat and detergents.
There is no accumulation of protease-resistant ‘‘prion’’
protein (PrP) in the brain (Caughey and Portis, unpub-
lished data), and PrP-knockout mice are still susceptible
to CasBrE (Jolicoeur et al., 1996). The primary lesion
appears to represent swollen neuronal dendritic pro-
cesses (Lynch et al., 1991; Nagra et al., 1992), which
coalesce to form the holes visible with the light micro-
scope, though neuronal dropout is responsible for some
of the vacuoles. Curiously, early EM studies noted the
surprising absence of visible virus particles associated
with the degenerative lesions (Andrews and Gardner,
1974).
Over the past 20 years since the discovery of CasBrE,
other murine retroviruses including additional members
of the ecotropic host range group (McCarter et al., 1977;
Wong et al., 1983; Kai and Furuta, 1984; Bilello et al., 1986;
Zachary et al., 1986; Simonian et al., 1990; Hoffman et al.,
1992; Czub et al., 1995a) as well as recombinant poly-
tropic (Buller et al., 1990) and amphotropic (Munk et al.,
1997) viruses have been found to be neuropathogenic.
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The diseases caused by the ecotropic viruses appear
essentially identical in clinical presentation and patho-
logical features to that caused by CasBrE. The neurolog-
ical disease caused by the polytropic viruses is distinct
in that spongiform degeneration is minimal, glial activa-
tion is a dominant feature, and the disease is clinically
manifested by initial hyper-excitability followed by ataxia
and terminal immobility (Portis et al., 1995). In addition,
virus distribution in the brain is more restricted than that
seen in the ecotropic viral diseases (Portis et al., 1995).
There are two additional retrovirus-induced diseases
that are quite different from the others but will not be
discussed here: an acute cerebrovascular hemorrhagic
disease caused by a variant of Friend MuLV, TR1.3 (Park
et al., 1994) and a cognitive disorder associated with the
immunodeficiency induced by the MAIDS virus complex
LPBM5 (Kustova et al., 1996).
Viral and host determinants of neuropathogenesis
Molecular cloning of CasBrE in the early 1980s (Joli-
coeur et al., 1983) made possible the construction of
chimeric viral genomes, which demonstrated that the
envelope gene harbors the principal determinants of
neurovirulence (DesGroseillers et al., 1984). Similar map-
ping studies on the other neurovirulent viruses have
confirmed the role of env in neuropathogenesis (Yuen et
al., 1985; Portis et al., 1990, 1995; Munk et al., 1997). The
envelope gene of oncornaviruses, like the lentiviruses,
encodes two proteins, the surface glycoprotein (SU) and
the transmembrane protein (TM) involved in receptor
binding (Kabat, 1989; Heard and Danos, 1991) and fusion
(Rein et al., 1998) respectively. Mapping studies indicate
that neurovirulence determinants of CasBrE are located
in the SU component (Paquette et al., 1989).
There are, however, other sequences that influence
neuropathogenesis, and their location is illustrated in
Fig. 1. While CasBrE is neuropathogenic, it is only weakly
neuroinvasive and causes disease with a long incuba-
tion period. In contrast, a strain of Friend MuLV, FB29, is
highly neuroinvasive but does not cause neurological
disease. Introduction of the envelope gene of CasBrE
into the genome of FB29 created the chimeric virus
FrCasE, which, like FB29, is highly neuroinvasive but also
causes a rapidly fatal spongiform neurodegenerative dis-
ease (Portis et al., 1990). For viruses carrying the CasBrE
envelope gene, the tempo and severity of the disease is
a function of viral burden in the brain (Czub et al., 1992),
and this in turn is determined by sequences from FB29.
FIG. 1. Schematic summary of mapping studies illustrating the separation of sequences that influence neuroinvasiveness from those determining
neurovirulence. All mice were inoculated intraperitoneally (ip) as neonates with the same dose of virus. The two parental viruses CasBrE and FB29
are shown at the top and various chimeric viruses below. The gag and glycosylated gag (‘‘glycogag’’) proteins are shown above the genome of CasBrE.
Glycogag is translated from an alternate initiation site upstream of, and in-frame with, the start codon of the gag proteins of the virion core. Thus, the
coding sequences of gag and glycogag are identical, except for an extra 88 residues at the N terminus of glycogag, which represents the cytoplasmic
tail of this integral membrane protein. The asterisk (*) above the genome of KPgg- indicates the location of mutations in the ‘‘Kozak’’ consensus
sequence which interrupt translation of glycogag. ‘‘Viral burden’’ in the brain has been measured by several methods including Southern blot for viral
DNA, immunoblot for viral protein, infectious center assays as well as immunohistochemistry. ‘‘Disease’’ is determined by observation of clinical status
and ‘‘Incubation Period’’ represents the length of time (days) between inoculation and the first signs of clinical disease (NA-not applicable). This
schematic illustrates several points: (1) Neurovirulence maps to the viral envelope gene. Unless a virus contains the CasBrE envelope gene, disease
is not observed, irrespective of the magnitude of viral burden in the brain. (2) For viruses containing the CasBrE envelope gene, the tempo of the
disease is directly related to viral burden in the brain. And (3) viral burden (neuroinvasiveness) is determined by sequences within the viral LTR and
the cytoplasmic tail of glycogag.
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Construction of additional chimeric genomes (Fig. 1, bot-
tom) localized the relevant sequences from FB29 to the
viral LTR, containing the promoter and transcriptional
enhancers for viral RNA synthesis, and the 59 leader
sequence of the viral genome, 59 of the initiation codon
for the precursor of the gag proteins of the viral core
(Portis et al., 1994). This region, which has been called
the 59 untranslated region, actually encodes a protein
called glycosylated gag (Fig. 1), a Type 2 integral mem-
brane protein that is conserved in both murine (Tung et
al., 1976; Evans et al., 1977) and feline (Neil et al., 1980;
Laprevotte et al., 1984) oncornaviruses, but the function
of which is unknown. Virus dissemination to the brain is
affected by the sequencing encoding the N-terminal cy-
toplasmic tail of the protein (Portis et al., 1994; Fujisawa
et al., 1998) (Fig. 1). These genetic studies, thus, have
uncovered a dissociation between neuroinvasiveness
and neurovirulence, both properties being important for
the expression of the neuropathogenic phenotype.
How then do the viral LTR and glycosylated gag influ-
ence neuroinvasiveness? Both of these elements deter-
mine the kinetics of virus spread in peripheral nonneural
tissues during the first few days after neonatal inocula-
tion (Portis et al., 1994). FB29 and FrCasE reach peak
viremia titers within 5 day of inoculation, whereas Cas-
BrE is significantly slower by 3 to 4 day (Czub et al.,
1992). This delay is critical because of a progressive
resistance of the brain to infection, which appears post-
natally as a function of age (Brooks et al., 1981; Czub et
al., 1991). Resistance is first noted on postnatal Day 6
(P6) and is essentially complete by P10. It is independent
of antiviral immunity and cannot be bypassed even by
direct intracerebral inoculation of virus (Czub et al., 1991).
The mechanism of resistance is as yet unclear but may
involve a loss of susceptibility of brain microvascular
endothelial cells (Lynch et al., 1995), the portal of entry of
these viruses into the brain (Swarz et al., 1981; Pitts et al.,
1987; Czub et al., 1994). Although neuroinvasion from the
periphery is restricted, local spread of virus within the
brain parenchyma (i.e., beyond the microvasculature)
continues, but at a relatively slow pace (Czub et al., 1994;
Lynch et al., 1995; Robertson et al., 1997). Thus, viral
burden in the brain can be viewed at two levels, initial
neuroinvasion from the periphery, dependent on suscep-
tibility of brain endothelial cells, and the subsequent
virus spread within the brain.
By virtue of the age-dependent resistance of the brain,
neuroinvasion is influenced by any factors that affect the
extent of virus spread in the periphery during the first few
days after neonatal inoculation. This is accomplished
artificially by altering the dose of the inoculum (Brooks et
al., 1979; Hoffman et al., 1981; Czub et al., 1992) or the
time of inoculation (Hoffman et al., 1981; Sharpe et al.,
1987; Czub et al., 1991). Protective immunity appears not
to play a significant role in limiting virus spread at this
early time point. Mice inoculated with oncornaviruses as
neonates exhibit markedly restricted immune responses
with no detectible protective humoral or cellular immu-
nity (Huebner et al., 1971; Hoffman et al., 1984; Korostoff
et al., 1990; Sarzotti et al., 1996). The hyporesponsive-
ness is virus-specific and, for some viruses, may be
related to infection of the thymus during the perinatal
period (Gaulton, 1998). Genetic resistance mechanisms
have been described, and these do function during the
neonatal period. Resistance genes have been identified
in wild mice [Akvr-1 (Gardner et al., 1980) and FV-4 (Ikeda
and Sugimura, 1989)] as well as laboratory mice (RMCF;
Ruscetti et al., 1981; Buller et al., 1988). These genes
encode endogenous retroviral envelope proteins that
function by interfering with receptor availability. Interest-
ingly, receptor blockade can be achieved artificially by
prior inoculation of laboratory mice with nonpathogenic
retroviruses that use the same receptor as the patho-
genic strain (Corbin and Sitbon, 1993; Czub et al., 1995b).
FV-1, a recently cloned resistance gene (Best et al., 1996)
that produces strong resistance to neurological disease
induced by CasBrE (Oldstone et al., 1980), encodes an
endogenous retroviral gag protein, which interferes with
an early postentry step in the virus life cycle (Jolicoeur
and Baltimore, 1976). Mouse genetic studies have re-
vealed the existence of other resistance genes (Oldstone
et al., 1980; Hoffman and Morse, 1985; Buller et al., 1990),
though they have not been further characterized.
The aforementioned viral and host determinants either
promote or restrict access of virus to the brain. Another
type of host effect was observed during experiments in
which the highly neurovirulent virus FrCasE (Fig. 1) was
inoculated in utero into midgestation embryos (Lynch
and Portis, 1993). Because of the rapidity of spread of the
virus, it was anticipated that the fetuses might not sur-
vive to parturition. The virus, indeed, infected the brain in
utero and achieved levels of viral burden in the brain far
exceeding that seen in neonatally inoculated mice. Yet
pathological and clinical signs of disease appeared at
the same postnatal days as observed in neonatally in-
oculated mice (P10 and P15, respectively), indicating that
P10 was a critical time point before which the brain
appeared refractory to the neuropathogenic effects of
virus infection. The nature of this developmental resis-
tance is not known.
What cells are infected in the brain?
Because the mouse genome is replete with endoge-
nous retroviral sequences (Best et al., 1997), it was im-
portant in searching for the identity of the infected cells
to use probes that would detect only the inoculated virus.
Although there is extensive homology among murine
oncornaviruses, the envelope gene as well as se-
quences of the U3 region of the viral LTR exhibit suffi-
cient sequence diversity to generate reagents specific
for CasBrE. CasBrE-specific nucleic acid probes (Rassart
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et al., 1986; Portis et al., 1990) and monoclonal antibodies
(McAtee and Portis, 1985) have identified a variety of
cells in the brain infected by CasBrE and its derivatives
(Kay et al., 1991; Lynch et al., 1991). As mentioned above,
the first cells to be infected are microvascular endothe-
lial cells where the virus amplifies. The vascular infec-
tion, while impressive and sometimes productive of strik-
ing accumulations of virus particles (Oldstone et al.,
1977; Swarz et al., 1981; Lynch et al., 1991), appears not
to disrupt the blood-brain barrier (Nagra et al., 1992).
Infected cells of the brain parenchyma are essentially of
two types, microglial cells and neurons. Infection of neu-
roglia (astrocytes and oligodendrocytes) is seen (Old-
stone et al., 1977) but is rare (Gravel et al., 1993). Infected
neurons have been identified in the cerebellar cortex,
hippocampus, and olfactory bulb (Kay et al., 1991; Lynch
et al., 1991; Gravel et al., 1993), populations of neurons
that are distinguished by their proliferation postnatally
(Miale and Sidman, 1961). Interestingly, although infec-
tion of these neuronal populations is fully permissive
(Lynch et al., 1991), these cells never exhibit signs of
cytopathology (Lynch et al., 1991; Gravel et al., 1993).
There is some disagreement in the literature concern-
ing the question of whether neurons within the areas of
the CNS exhibiting neurodegenerative lesions are in-
fected by this virus. This is not a trivial issue because
these neurons are thought to be largely nonmitotic after
midgestation and their infection by CasBrE (inoculated
into neonates) would suggest that this virus was unique
among murine oncornaviruses in productively infecting
nondividing cells (Oldstone et al., 1977, 1983). Indeed,
initial ultrastructural studies on paralyzed CasBrE-in-
fected mice (Gardner et al., 1973; Andrews and Gardner,
1974) revealed C-type virus budding into intracellular
vesicles of motor neurons in the ventral horns of the
spinal cord, a finding that has been confirmed by others
(Oldstone et al., 1977, 1980, 1983; Swarz et al., 1981)
including ourselves (Portis, 1990). In addition, oncorna-
viral proteins have been found in these cells by immu-
nohistochemical techniques using detecting reagents
such as polyclonal antisera to CasBrE whole virus (Old-
stone et al., 1977) or viral proteins (Morey and Wiley,
1990; Sharpe et al., 1990). However, neither EM nor
immunodetection with polyclonal antisera would distin-
guish the inoculated virus from an endogenous retrovirus
expressed perhaps as a consequence of neuronal injury.
Polyclonal antisera to oncornaviral proteins are charac-
teristically broadly reactive with a variety of both exoge-
nous and endogenous viruses. In contrast to these find-
ings, application of CasBrE-specific probes to address
this question in both slow and rapid forms of the disease
has consistently failed to detect expression of the inoc-
ulated virus in these neurons (Kay et al., 1991; Lynch et
al., 1991; Gravel et al., 1993). In the rapid disease caused
by derivatives of CasBrE, evidence of viral protein ex-
pression in these neurons has also not been forthcom-
ing, even using broadly reactive reagents (see Fig. 2).
Thus, it appears more likely that virus expression de-
tected in these nondividing neurons is not the result of
infection but instead represents the activation of an en-
dogenous provirus harbored in the germline of the
mouse and may be a late occurrence seen only in more
chronic forms of disease. CasBrE, thus, would appear to
obey the same rules as the other oncornviruses in re-
quiring cell division for productive infection (Hajihosseini
et al., 1993), a conclusion that is supported by in vitro
studies (Lynch et al., 1994). Collectively these observa-
FIG. 2. These are photomicrographs of the brain stem of a mouse
neonatally inoculated ip with the CasBrE derivative KP (Fig. 1) and
killed in the terminal stage of clinical disease 22 days later. Paraffin
embedded sections were subjected to antigen-retrieval (Shi et al.,
1993) and stained with a polyclonal anti-SU antiserum using immuno-
peroxidase. Spongiform degeneration, seen at low magnification as
collections of holes in the tissue (A), colocalizes with the infected cells
(stained red), which, in this location, consist primarily of microglia
(Lynch et al., 1991; Gravel et al., 1993). At higher power, the processes
of infected microglia are seen to be associated with microvacuoles in
the neuropil between neurons (B) and with a neuron cell body exhib-
iting cytoplasmic swelling characteristic of ‘‘hydropic’’ degeneration (C,
arrow). The degenerating cell body is identified as a neuron by its
nuclear morphology, which resembles that of other intact neurons in
the same field (C, arrowheads). Note that the neurons are negative for
viral envelope protein. Magnifications: (A), 330; and (B and C), 3125
before enlargement.
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tions indicate that, although some populations of neu-
rons which divide postnatally are productively infected
by CasBrE and its derivatives, this infection is not cyto-
toxic. In contrast, the neurons that degenerate appear
not to be infected, leading one to the conclusion that the
neuronal injury induced by this virus is a consequence of
indirect mechanisms.
Infected microglial cells are abundant in this disease
(Lynch et al., 1991; Gravel et al., 1993), and it is these
cells that co-localize with the spongiform lesions (Fig. 2).
Unlike the neuroglia, which are of neuroectodermal ori-
gin, microglial cells are of mesodermal origin (Hickey et
al., 1992; Theele and Streit, 1993) and are thought to be
the resident macrophages of the brain. The importance
of microglial infection has been strengthened by similar
findings in the diseases caused by a neurovirulent vari-
ant of Moloney MuLV, ts1 (Baszler and Zachary, 1990,
1991), a rat adapted variant of Friend MuLV, NT-40 (Czub
et al., 1995a) as well as the recombinant amphotropic
virus, Mo-AmphoV (Munk et al., 1997). Furthermore, stud-
ies of a neurovirulent polytropic virus Fr98 (Portis et al.,
1995) and its derivatives (Hasenkrug et al., 1996) has
revealed a direct relationship between the frequency of
infected microglia and the occurrence of clinical disease
(Robertson et al., 1997).
Microglial cells and spongiform degeneration
To address directly the importance of microglia in
neuropathogenesis, infected primary microglial cells
were implanted into the brains of mice at P10, a time
point at which spread of virus to recipient brain cells is
restricted. The virus used for these studies was FrCasE,
the highly neuropathogenic derivative of CasBrE (Fig. 1).
The implanted microglia assumed an highly ramified
morphology, persisted for several weeks, migrated within
the ipsi- and contralateral hemispheres and continued to
express viral proteins. Three weeks after implant, focal
spongiform lesions were detected in the immediate vi-
cinity of the infected microglia (Lynch et al., 1995). Im-
plantation of uninfected microglia failed to induce le-
sions. These experiments indicated that infected micro-
glia alone were sufficient for induction of lesions, but did
not reveal whether they were necessary or obligate par-
ticipants.
To address this issue, a neural progenitor cell line
(C17–2) (Ryder et al., 1990) was used which, when trans-
planted into the neonatal mouse brain intraventricularly,
is incorporated into the subventricular germinal matrix
and is disseminated widely throughout the brain (Snyder
et al., 1992). These cells differentiate into neurons, as-
trocytes, and oligodendrocytes, which become inte-
grated into the normal CNS cytoarchitecture and persist
for extended periods (Snyder et al., 1997; Taylor and
Snyder, 1997). What is significant, however, is that C17–
2 are of neuroectodermal origin and do not differentiate
into microglia, providing a means of expressing virus in
the brain from a source which is unrelated to microglial
cells. The C17–2 cells were productively infected with a
highly neurovirulent derivative of CasBrE [CasFrL (Fig. 1)]
and injected intraventricularly into neonatal FV-1 incom-
patible mice. As mentioned above, FV-1 is a resistance
gene that interferes with an early postentry step in the
replication cycle. Although these virus-producing cells
engrafted in regions of the brain that were susceptible to
the virus, in numbers comparable to that seen in neona-
tally inoculated mice, lesions were not observed (Lynch
et al., 1996). In contrast, FrCasE, which was FV-1 com-
patible with the recipient mouse and spread unrestricted
to recipient microglia, induced typical spongiform le-
sions. In a separate experiment, C17–2 cells expressing
only the envelope protein of CasBrE were implanted.
Here no infectious virus was present, only cells express-
ing high and sustained levels of envelope protein. No
lesions were observed in these brains (Lynch et al.,
1996). We can conclude from these implantation experi-
ments that (1) infected microglial cells are both neces-
sary and sufficient for induction of the spongiform le-
sions; (2) the envelope protein of CasBrE is not directly
neurotoxic in vivo; and (3) neurotoxicity is not a conse-
quence of virus/receptor interactions at the cell surface,
a conclusion drawn from the fact that FV-1 restriction
occurs at a postentry step. In short, the results of the
implants would argue that it is productive infection of
microglial cells that is responsible for the neurovirulence
of these viruses.
Role of the viral envelope protein
Clearly, the envelope gene harbors important determi-
nants of neurovirulence (Fig. 1). If the envelope protein is
not neurotoxic, then what is its role in neuropathogen-
esis? Some clues have come from mapping studies. In
two unrelated viruses, PVC-211 (ecotropic) (Masuda et
al., 1993) and Fr98 (polytropic) (Hasenkrug et al., 1996),
the relevant sequences within the envelope gene that
determine neurovirulence are located in the N-terminal
half of the surface glycoprotein (SU). This part of the
protein contains the receptor-binding domain (Battini et
al., 1995; MacKrell et al., 1996; Davey et al., 1997). Based
on the recently crystallized receptor binding domain of
the Friend MuLV SU protein (Fass et al., 1997), one of two
critical residues of PVC-211 (G116) appears to be close to
the putative receptor binding surface of the molecule.
Interestingly, these residues enhance the ability of PVC-
211 to infect brain capillary endothelial cells (Masuda et
al., 1996) and thus are likely to have a strong influence on
the extent of neuroinvasion occurring during the perina-
tal period. In the case of Fr98, the sequence of the
N-terminal half of SU influences the kinetics of virus
spread within the brain parenchyma, specifically to mi-
croglial cells during the period 3 to 8 week postinocula-
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tion (Hasenkrug et al., 1996; Robertson et al., 1997). Thus,
in both cases, sequences that influenced neurovirulence
also appear to influence viral tropism in the brain, and it
is possible that this effect alone could explain the role of
the viral envelope protein in this disease.
While the implant experiments indicated that the en-
velope protein was not neurotoxic when expressed in the
brain by C17–2 cells, there is some evidence that expres-
sion of only the viral envelope protein in the brain may be
neuropathogenic under certain conditions. Mice carrying
either the CasBrE (Kay et al., 1993) or ts-1 Moloney (Yu et
al., 1997) envelope genes as transgenes, driven by the
respective viral promoters, do indeed develop focal
spongiform lesions. In both cases, expression levels in
the brain were extremely low (detectable only by RNAase
protection assay), incubation periods were very long (1 to
2 year) and clinical manifestations were minimal at best.
The difference in the results obtained with these two
approaches (implants vs transgenic mice) might be ex-
plained by the identity of the cells expressing the protein.
In the C17–2 implants, the cells were of neuroectodermal
origin. In the transgenics, though the env-expressing
cells were not actually identified, the viral promoters
used in both cases function well in microglial cells (Bas-
zler and Zachary, 1991; Gravel et al., 1993). Thus, together
these experiments suggest that expression of the enve-
lope gene alone in microglial cells might be sufficient to
induce lesions. Whether the sequence of the envelope
protein expressed in microglia influences neurovirulence
was not addressed in these experiments. It is also un-
clear that the effect is env-specific at all. Thus, expres-
sion of other viral genes in microglia may be equally
neuropathogenic. These questions can perhaps best be
addressed by studying viruses such as FB29 (Fig. 1)
which are neuroinvasive, but not neurovirulent.
Does glial activation play a role in disease induction?
Through manipulation of the virus and the host it has
been possible to separate factors relevant to neuroviru-
lence of the murine oncornaviruses from those that rep-
resent epiphenomena. One pathological change that is
observed in all the more chronic forms of neurological
disease caused by these viruses is the occurrence of
reactive gliosis, manifested by immunohistochemical
signs of microglial and astocytic activation. Microglia are
exquisitely sensitive to even subtle perturbations of the
nervous system, transforming from highly ramified ‘‘qui-
escent’’ cells to actively phagocytic ‘‘amoeboid’’ microglia,
which can present antigen and participate in local im-
mune responses (Kreutzberg, 1996; Streit, 1996). Micro-
glial activation appears to be the first line of defense of
the brain to invading microbes. Thus, it is not surprising
that these cells would be activated in response to neu-
roinvasive viruses. However, it has been proposed that
glial activation, and specifically microglial activation, is
implicated causally in a number of chronic degenerative
diseases such as HIV encephalopathy (Lipton, 1997;
Gendelman and Tardieu, 1994), Alzheimer’s disease
(Martin et al., 1994; Frautschy et al., 1998), and prion
diseases (Brown et al., 1996). Indeed, the best correlate
of the dementia associated with HIV infection of the brain
is not the frequency of virus infected cells, but the fre-
quency of activated macrophage/microglial cells (Glass
et al., 1995; Tyor et al., 1995). These cells can secrete a
variety neurotoxic substances in vitro including a cyto-
kines, reactive oxygen species and NMDA receptor ago-
nists (Lipton, 1997). However, some of the cytokines
expressed by these cells also have neuroprotective ef-
fects (Barger et al., 1995; Strijbos and Rothwell, 1995;
Bruce et al., 1996) and activated microglia produce bona
fide neurtrophins (Elkabes et al., 1996). Thus, it is not
always clear whether the activation of these cells in vivo
is harmful or helpful.
In the case of the murine oncornaviruses, there is
evidence from several quarters that neurovirulence
may be separable from microglial activation. (1) Both
neurovirulent and avirulent polytropic viruses induce
intense microglial activation in the same regions of the
brain (Robertson et al., 1997), indicating that glial ac-
tivation alone is not sufficient to precipitate clinical
disease. (2) In the microglial implantation experiments
described above, focal spongiform lesions were spa-
tially associated with infected microglial cells, but
these cells did not express cell-surface activation
markers (Lynch et al., 1995). And (3) FrCasE, the highly
neurovirulent derivative of CasBrE, infects large num-
bers of microglial cells and induces a rapidly fatal
spongiform degeneration that is widespread already
at 14 days postinoculation, yet, again, without expres-
sion of cell-surface markers indicative of microglial
activation (Lynch et al., 1991; Czub et al., 1994). Simply
diluting the virus inoculum so as to delay the onset of
clinical disease, resulted in the appearance of intense
gliosis (Czub et al., 1994), indicating that FrCasE is
capable of inducing glial activation so long as the
mice lived long enough.
Concluding remarks
Although the function of microglia in initiating local
immune responses and as the scavengers of the brain is
well accepted, these cells also appear to play important,
but poorly understood, roles in neural support. The im-
plantation studies outlined above indicate that the neu-
rovirulence of the murine oncornaviruses is tightly linked
to the expression of one or more viral genes by micro-
glial cells but that the products of those genes are not
themselves neurotoxic. Certainly this scenario is consis-
tent with the hypothesis that infection might induce the
expression of neurotoxins by these cells. However, the
unexpected lack of correlation with microglial activation
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leaves open the possibility that the neurovirulence of
these viruses is effected by a loss of microglial function.
Gaining a better understanding of the effect of these
viruses on the biology of the microglial cell in vivo is
likely to teach us as much about the pathogenesis of
these brain diseases as it is about the special functions
of these cells.
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